Insulin and coronary artery disease: Is syndrome X the unifying hypothesis?

Annals of Pharmacotherapy

Volumn 32, Issue 2, 1998, Pages 233-247

  Baillie, G Mark ^a   Sherer, Jeffrey T ^b,c   Weart, C Wayne ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Coronary artery disease; Insulin; Syndrome X

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; METFORMIN; TROGLITAZONE;

ATHEROGENESIS; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN METABOLISM; INSULIN RESISTANCE; LIFESTYLE; NONHUMAN; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYNDROME X;

EID: 0031894423     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.13398     Document Type: Review

References (124)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-607.
2. Cannon RO, Camici PG, Epstein SE. Pathophysiological dilemma of syndrome X. Circulation 1992;85:883-92.
3. Kaplan NM. The deadly quartet. Arch Intern Med 1989;149:1514-20.
4. Stern MP, Mark AL. Syndrome X: is it a significant cause of hypertension? Hosp Practice 1992;27(suppl 1):37-45.
5. Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders: the mechanism of "syndrome X." Am J Hypertens 1993;6:S123-34.
6. Hales CN. The pathogenesis of NIDDM. Diabetologia 1994;37(suppl 2):S162-8.
7. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. N Engl J Med 1991;325:938-48.
8. Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 1994;343:91-5.
9. Swislocki ALM, Chen YDI, Golay A, Chang MO, Reaven GM. Insulin suppression of plasma-free fatty acid concentration in normal individuals and patients with type 2 (non-insulin-dependent) diabetes. Diabetologia 1987;30:622-6.
10. Golay A, Chen YDI, Reaven GM. Effect of differences in glucose tolerance on insulin's ability to regulate carbohydrate and free fatty acid metabolism in obese individuals. J Clin Endocrinol Metab 1986;62:1081-8.
11. Stewart MW, Humphriss DB, Berrish TS, Barriocanal LA, Trajano LR, Alberti KGMM, et al. Features of syndrome X in first-degree relatives of NIDDM patients. Diabetes Care 1995;18:1020-2.
12. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992; 340:925-9.
13. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237: E214-23.
14. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-65.
15. Reaven GM, Chen Y-DI. Insulin resistance, its consequences, and coronary heart disease: must we choose one culprit (editorial)? Circulation 1996;93:1780-3.
16. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994;236(suppl): 13-22.
17. Stout RW. Insulin and atheroma: 20 year perspective. Diabetes Care 1990;14:634-54.
18. Wing RR, Matthews KA, Kuller LH, Smith D, Becker D, Plantinga PL, et al. Environmental and familial contributions to insulin levels and change in insulin levels in middle-aged women. JAMA 1992;268:1890-5.
19. Stern MP, Haffner SM. Body fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular disease. Atherosclerosis 1986;6:123-30.
20. Larsson B, Svardsudd K, Welin L, Wilhelmsen L, Bjorntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow-up of participants in the Study of Men Born in 1913. Br Med J 1984;288:1401-4.
21. Seidell JC, Bakker CJG, Van der Kooy K. Imaging techniques for measuring adipose tissue distribution: a comparison between computed tomography and I.S.T. magnetic resonance. Am J Clin Nutr 1990;51:953-7.
22. 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995; 333:348-51.
23. 3-adrenergic-receptor gene. N Engl J Med 1995;333: 343-7.
24. Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. Diabetes 1993;42:1700-7.
25. Barrett-Connor E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes. Ann Intern Med 1992;117: 807-11.
26. Zavaroni I, Dall' Aglio E, Alpi O, Bruschi F, Bonora E, Pezzarrossa A, et al. Evidence for an independent relationship between plasma insulin and concentration of high density lipoprotein cholesterol and triglycerides. Atherosclerosis 1985;55:259-66.
27. Reaven GM, Lerner RL, Stern MP, Farquhar JW. Role of insulin in endogenous hypertriglyceridemia. J Clin Invest 1967;46:1756-67.
28. Olefsky JM, Farquhar JW, Reaven GM. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974;57:551-60.
29. Laws A, Reaven GM. Insulin resistance, hyperinsulinemia, dyslipidemia, and cardiovascular disease. In: Braunwald E, ed. Heart disease update. 4th ed. Philadelphia: WB Saunders Co., 1992:1-9.
30. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988;260:1917-21.
31. Simonson DC, Dzau VJ. Workshop IX: lipids, insulin, diabetes. Am J Med 1991;90(suppl 2A):S85-6.
32. Vuorinen-Markkola H, Yki-Jarvinen H, Taskinen MR. Lowering of triglycerides by gemfibrozil affects neither the glucoregulatory nor the antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:161-9.
33. Fraze E, Dornner CC, Swislocki ALM, Chiou YAM, Chen YDI, Reaven GM. Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 1985;61:807-11.
34. Laws A, Reaven GM. Evidence for an independent relationship between insulin resistance and fasting plasma HDL cholesterol, triglyceride, and insulin concentrations. J Intern Med 1992;231:25-30.
35. Manolio TA, Savage PJ, Burke GL, Liu K, Wagenknecht LE, Sidney S, et al. Association of fasting insulin with blood pressure and lipids in young adults: the CARDIA study. Arteriosclerosis 1990;10:430-6.
36. Barakat HA, Carpenter JW, McLendon VD, Khazanie P, Leggett N, Heath J, et al. Influence of obesity, impaired glucose tolerance, and NID-DM on LDL structure and composition: possible link between hyperinsulinemia and atherosclerosis. Diabetes 1990;39:1527-33.
37. Reaven GM, Chen Y-D, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in patients with small, dense, low density lipoprotein particles. J Clin Invest 1993;92:141-6.
38. Feher MD. Hypertension in non-insulin dependent diabetes mellitus and its management. Postgrad Med J 1991;67:938-46.
39. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension: a meta-analysis. Arch Intern Med 1992;152:1649-51.
40. Caro JF. Insulin resistance in obese and non-obese men. J Clin Endocrinol Metab 1991;73:691-5.
41. Randeree HA, Omar MAK, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992;15:1258-63.
42. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension: the San Antonio Heart Study. Arch Intern Med 1996;156: 1994-2000.
43. Ferrannini E, Buzzigoli G, Bonadonna R, Giorcia MA, Oleggini M, Graziadei L, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
44. Reaven GM. Relationship between insulin resistance and hypertension. Diabetes Care 1991;14(suppl 4):33-8.
45. Rutherford PA, Thomas TH, Wilkinson R. Insulin resistance and hypertension: implications for treatment. Postgrad Med J 1991;67:869-75.
46. Weidmann P, Trost BN. Pathogenesis and treatment of hypertension associated with diabetes. Horm Metab Res Suppl 1985;15:51-8.
47. Reaven GM, Hoffman BB. A role for insulin in the aetiology and course of hypertension? Lancet 1987;2:425-6.
48. Skott P, Vaag A, Braun NE, Hother-Nielsen O, Gall MA, Beck-Nielsen H, et al. Effect of insulin on renal sodium handling in hyperinsulinaemic type 2 (non-insulin-dependent) diabetic patients with peripheral insulin resistance. Diabetologia 1991;34:275-81.
49. Falkner B, Hulman S, Kushner H. Hyperinsulinemia and blood pressure sensitivity to sodium in young blacks. J Am Soc Nephrol 1992;3:940-6.
50. Daly PA, Landsberg L. Hypertension in obesity and NIDDM: role of insulin and sympathetic nervous system. Diabetes Care 1991;14:240-8.
51. Rimm EB, Manson JE, Stampfer MJ, Colditz WC, Willett WC, Rosner B, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993;83:211-4.
52. Facchini FS, Hollenbeck CB, Jeppesen J, IdaChen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992;339:1128-30.
53. Janzon L, Berntorp K, Hanson M, Lindell SE, Trell E. Glucose intolerance and smoking: a population study of oral and intravenous glucose tolerance tests in middle-aged men. Diabetologia 1983;25:86-8.
54. Eliasson B, Taskinen M, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996; 94:878-81.
55. Godsland IF, Wynn V, Walton C, Stevenson JC. Insulin resistance and cigarette smoking (letter). Lancet 1992;339:1619-20.
56. Duff GL, McMillan GC. The effects of alloxan on experimental atherosclerosis in the rabbit, I: the inhibition of experimental cholesterol atherosclerosis in alloxan diabetes. J Exp Med 1949;89:611-9.
57. Duff GL, McMillan GC. The effects of alloxan on experimental atherosclerosis in the rabbit, II: the effect of alloxan diabetes on the retrogression of experimental cholesterol atherosclerosis. J Exp Med 1949;89: 620-30.
58. Duff GL, Brechin DJH, Finkelstein WE. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit, IV: the effect of insulin therapy on the inhibition of atherosclerosis in the alloxan-diabetic rabbit. J Exp Med 1954;100:371-80.
59. Stamler J, Pick R, Katz LN. Effect of insulin in the induction and regression of atherosclerosis in the chick. Circ Res 1960;8:572-6.
60. Cruz AB, Amatuzio DS, Grande F, Hay LJ. Effect of intra-arterial insulin on tissue cholesterol and fatty acids in alloxan-diabetic dogs. Circ Res 1961;9:39-43.
61. Rubenstein AH, Seftel HC, Miller K, Bersohn I, Wright AD. Metabolic responses to oral glucose in healthy South African white, Indian, and African subjects. Br Med J 1969;1:748-51.
62. Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population: sixteen-year follow-up study. Diabetes 1974;23:105-11.
63. Logan RL, Riemersma RA, Thomson M, Oliver MF, Olsson AG, Walldius G, et al. Risk factors for ischemic heart disease in normal men aged 40: Edinburgh-Stockholm Study. Lancet 1978;1:949-55.
64. Welborne TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60.
65. Cullen K, Stenhouse NS, Wearne KL, Welborne TA. Multiple regression analysis of risk factors for cardiovascular disease and cancer mortality in Busselton, Western Australia - 13 year study. J Chron Dis 1983; 36:371-7.
66. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9.5 year follow-up of the Helsinki Policeman Study population. Acta Med Scand 1985;701(suppl):38-52.
67. Fontbonne A, Tchobroutsky G, Eschwege E, Richards JL, Claude JR, Rosselin GE. Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes 1988; 12:557-65.
68. Zavaroni I, Bonora E, Pagliara M, Dall'Aglio E, Luchetti L, Buonanno G, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med 1989; 320:702-6.
69. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G. Hyperinsulinemia is not a major coronary risk factor in elderly men: the Study of Men Born in 1913. Diabetologia 1992;35:766-70.
70. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
71. Howard G, O'Leary DH, Zaccaro D, Haffner S, Rewers M, Hamman R, et al. Insulin sensitivity and atherosclerosis. Circulation 1996;93:1809-17.
72. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet 1990;1:1373-6.
73. Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease. Lancet 1996;347:349-50.
74. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975;55:845-55.
75. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75: 1028-36.
76. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, Declerck PJ, et al. Plasma plasminogen activator inhibitor-1 in angina pectoris: influence of plasma insulin and acute-phase response. Arteriosclerosis 1989;9:362-7.
77. Paternostro-Bayles M, Wing RR, Robertson RJ. Effect of life-style activity of varying duration on glycémic control in type II diabetic women. Diabetes Care 1989;12:34-7.
78. Manson JE, Nathan DM, Krolewski AS, Stampfer MJ, Willett WC, Hennekens CH. A prospective study of exercise and incidence of diabetes among US male physicians. JAMA 1992;268:63-7.
79. Rogers MA, Yamamoto C, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Improvement in glucose intolerance after 1 week of exercise in patients with mild NIDDM. Diabetes Care 1988;11:613-8.
80. Eriksson KF, Lingarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo feasibility study. Diabetologia 1991;34:891-8.
81. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991;325:147-52.
82. Barnard RJ, Ugianskis EJ, Martin DA, Inkeles SB. Role of diet and exercise in the management of hyperinsulinemia and associated atherosclerotic risk factors. Am J Cardiol 1992;69:440-4.
83. Steinberg HO, Brechtel G, Johnson A, Baron AD. Insulin modulates endothelium derived relaxing factor/nitric oxide dependent vasodilation in skeletal muscle. Hypertension Dallas 1993;22:74-436.
84. Baron AD. Hemodynamic actions of insulin. Am J Physiol 1994;30: E187-202.
85. Colditz GA, Willett WC, Ronitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
86. Sharma AM. Effects of nonpharmacologic intervention on insulin sensitivity. J Cardiovasc Pharmacol 1992;20(suppl 11):S27-34.
87. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Granditis GA, Elmer PJ, et al. Treatment of Mild Hypertension Study: final results. JAMA 1993; 270:713-24.
88. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
89. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991;14(suppl 4):39-47.
90. Ravid M, Lang R, Rachmani R, Lischner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-9.
91. The National High Blood Pressure Education Program Working Group. National Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994;23:145-58.
92. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.
93. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.
94. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994;343:95-100.
95. Fontbonne A, Charles MA, Juhan-Vague I, Bard J, André P, Isnard F, et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care 1996;19:920-6.
96. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care 1993;16:621-9.
97. Crofford OB. Metformin. N Engl J Med 1995;333:588-9.
98. Chaisson JL. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet Med 1996;13(suppl 2):S23-4.
99. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
100. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
101. Ogihara T, Rakugi H, Ikegami H, Mikamia H, Masuo K. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hyertens 1995;8:316-30.
102. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 1993;329: 977-86.
103. The Diabetes Control and Complications Trial (DCCT) Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
104. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. H: Mortality results. Diabetes 1970;19:789-830.
105. Abraira C, Colwell J, Nuttall F, Sawin CT, Nagel NJ, Henderson W, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemie Control and Complications in Type II Diabetes. Arch Intern Med 1997;157:181-8.
106. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
107. Fore WW. Noninsulin-dependent diabetes mellitus: the prevention of complications. Med Clin North Am 1995;79:287-98.
108. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1 pt 2):136-45.
109. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996;19(suppl 1):S54-61.
110. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Arteriosclerosis 1992;95:69-76.
111. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-6.
112. Spencer CM, Barradell LB. Gemfibrozil: a reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Drugs 1996;51:982-1018.
113. Reaven GM. Are triglycerides important as a risk factor for coronary disease? Heart Dis Stroke 1993;2:44-8.
114. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-45.
115. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85:37-45.
116. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-9.
117. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
118. Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with Simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
119. Atorvastatin: a new lipid-lowering drug. Med Lett 1997;39:29-31.
120. Baller-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-33.
121. Jarrett RJ. Is insulin atherogenic (editorial)? Diabetologia 1988;31:71-5.
122. Jarrett RJ. In defence of insulin: a critique of syndrome X (editorial). Lancet 1992;340:469-71.
123. Anderson EA, Mark AL. The vasodilator action of insulin: implications for the insulin hypothesis of hypertension. Hypertension 1993;21:136-41.
124. Foster DW. Insulin resistance: a secret killer (editorial)? N Engl J Med 1989;320:733-4.